8 completed, 6 recruiting, 5 active not recruiting, 3 terminated. 12 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 4, Active not recruiting 3, Completed 3, Terminated 2 |
| Phase 2 | 12 | Completed 6, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Myeloproliferative Neoplasms: new trials by email Literature Review of Myeloproliferative Neoplasms trials Research Report on Myeloproliferative Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms Selinexor - Myeloproliferative Neoplasms | Phase 2 | Not yet recruiting | Zhongshan Hospital (Xiamen), Fudan University | 15 | 2026-07-01 | 2026-06-04 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 218 | 2026-05-11 | 2026-10-09 |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms INCA035784 - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 120 | 2025-10-01 | 2026-08-06 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation Ivosidenib, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | University of Chicago | 18 | 2024-09-19 | 2026-09-01 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms INCB160058, Standard disease-directed therapy - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 37 | 2024-08-08 | 2026-08-12 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Recruiting | Incyte Corporation | 290 | 2023-12-04 | 2026-04-17 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms INCA033989, Ruxolitinib - Myeloproliferative Neoplasms | Phase 1 | Active not recruiting | Incyte Corporation | 160 | 2023-09-25 | 2026-08-10 |
| A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms VAC85135, Ipilimumab - Myeloproliferative Neoplasms | Phase 1 | Completed | Janssen Research & Development, LLC | 14 | 2022-07-21 | 2025-07-20 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Jaktinib, azacitidine - Myelodysplastic Syndromes, Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 | 2021-09-30 | 2022-12-01 |
| Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells - Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 33 | 2021-02-15 | 2026-02-17 |
| A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Ipilimumab, CD25hi Treg depleted DLI - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 25 | 2019-07-10 | 2026-01-05 |
| A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms TQ05105 - Myeloproliferative Neoplasms | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 79 | 2018-11-20 | 2026-06-03 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders HSCT with TBI Regimen, HSCT with Non-TBI Regimen - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 300 | 2018-03-30 | 2026-06-25 |
| Registry of Patients With MPNs in Taiwan Myeloproliferative Neoplasms | Active not recruiting | Chang Gung Memorial Hospital | 500 | 2017-04-01 | 2025-02-14 | |
| Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders Myeloproliferative Neoplasms | Unknown | Assistance Publique - Hôpitaux de Paris | 300 | 2016-06-01 | 2018-03-29 | |
| A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms SGI-110 - Myeloproliferative Neoplasms | Phase 2 | Completed | Weill Medical College of Cornell University | 22 | 2016-03-15 | 2022-05-05 |
| Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Pemigatinib, Gemcitabine, Pembrolizumab - Lung Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 201 | 2015-02-27 | 2023-01-06 |
| A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders Anagrelide CR - Thrombocytosis, Myeloproliferative Neoplasms | Phase 2 | Completed | Galena Biopharma, Inc. | 18 | 2014-05-01 | 2017-02-27 |
| Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Ruxolitinib, Decitabine - Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Completed | John Mascarenhas | 49 | 2014-02-01 | 2019-02-28 |
Showing 20 of 24. Sign in to see all of them.
Myeloproliferative Disorders (24) · Primary Myelofibrosis (11) · Thrombocythemia, Essential (7) · Myelodysplastic Syndromes (5) · Leukemia, Myeloid, Acute (4) · Polycythemia Vera (4) · Leukemia, Myelomonocytic, Chronic (3) · Multiple Myeloma (3) · Anemia, Refractory, with Excess of Blasts (2) · Burkitt Lymphoma (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (2) · Leukemia, Prolymphocytic (2)
Bone Marrow Diseases (24) · Hemic and Lymphatic Diseases (24) · Hematologic Diseases (23) · Hemorrhagic Disorders (10) · Neoplasms (9) · Neoplasms by Histologic Type (8) · Blood Coagulation Disorders (7) · Blood Platelet Disorders (7) · Chronic Disease (7) · Disease Attributes (7) · Leukemia, Myeloid (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Thrombocytosis (6) · Leukemia (5)
ruxolitinib (4) · Decitabine (2) · Ipilimumab (2) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · Allopurinol (1) · Anthracyclines (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Busulfan (1) · Cisplatin (1) · Consolidation Chemotherapy (1) · Cytarabine (1) · Daunorubicin (1) · Docetaxel (1) · Filgrastim (1)
Incyte Corporation (6) · Memorial Sloan Kettering Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · Chang Gung Memorial Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Galena Biopharma, Inc. (1) · Hospital Israelita Albert Einstein (1) · Janssen Research & Development, LLC (1) · John Mascarenhas (1) · MPN Research Foundation (1) · Masonic Cancer Center, University of Minnesota (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1) · University of Chicago (1)
United States (16) · Germany (5) · France (4) · Italy (4) · United Kingdom (4) · Australia (3) · Canada (3) · Belgium (2) · China (2) · Denmark (2) · Japan (2) · Spain (2) · Brazil (1) · Norway (1) · South Korea (1)
Raajit Rampal, MD, PhD (2) · Anand Patel (1) · Asad Bashey, MD, PhD (1) · Fabio P Santos, MD (1) · John Koreth, MD (1) · John Mascarenhas, MD (1) · Nelson Hamerschlak, MD, PhD (1) · Pinkal Desai, MD (1) · Punita Grover, MD (1) · Richard J Lin, MD, PhD (1) · Ronald Hoffman, MD (1)
PMID 20674758, PMID 27774990, PMID 33104796, PMID 34951522, PMID 35176457
P01CA108671 (1), P01CA229092 (1), U10CA031946 (1)